IP Library Granted Patent US 11,105,807
Granted Patent B2
US 11,105,807 · App. 15/761,637 · Granted Aug 31, 2021

Method for estimating pathological tissue diagnosis result (Gleason score) of prostate cancer

Inventors: Tomonori Kaneko (Hachioji, JP); Takatoshi Kaya (Inagi, JP)
Assignee: KONICA MINOLTA, INC.
G01N33/57434G01N33/53G01N33/543G01N2440/38
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,105,807
App. No.
15/761,637
Granted
Aug 31, 2021
Kind
B2
Abstract

Provided is a method of obtaining an index value used for pathological tissue diagnosis of prostate cancer, which method has low invasiveness and can be performed at a low cost. The method is a method of estimating a Gleason score that represents the malignancy of prostate cancer, which method includes: measuring the content of a prostate-specific antigen having an N-acetylgalactosamine residue at a non-reducing terminal of a sugar chain in a sample; and estimating that the Gleason score is 7 or higher when the thus measured value is larger than a threshold value, or estimating that the Gleason score is 6 or lower when the measured value is smaller than a threshold value. The prostate-specific antigen is preferably quantified by a method including the step of binding a molecule having an affinity for β-N-acetylgalactosamine residue, such as Wisteria floribunda lectin, soybean agglutinin, Vicia Villosa lectin or an anti-β-N-acetylgalactosamine antibody, to the prostate-specific antigen.

Claims (10)

1. A method of determining a Gleason score that represents the malignancy of prostate cancer, said method comprising:

measuring the content of a prostate-specific antigen having an N-acetylgalactosamine residue at a non-reducing terminal of a sugar chain (GalNAc-PSA) in a sample;

comparing the measured content of GalNAc-PSA to a first threshold value for a Gleason score of 6 or lower, or comparing the measured content of GalNAc-PSA to a second threshold value for a Gleason score of 7 or higher; and

determining that the sample has a Gleason score of 7 or higher when the measured content of GalNAc-PSA is larger than the second threshold value, or determining that the sample has a Gleason score of 6 or lower when said measured content of GalNAc-PSA is smaller than the first threshold value,

wherein the measuring comprises binding to the GalNAc-PSA a molecule having affinity for β-N-acetylgalactosamine,

wherein said molecule having an affinity for a β-N-acetylgalactosamine residue is Wisteria floribunda lectin (WFA), soybean agglutinin (SBA), or Vicia Villosa lectin (VVL), and

wherein said PSA is quantified by surface plasmon-field enhanced fluorescence spectroscopy (SPFS).

2. The method according to claim 1 , wherein the first threshold value and the second threshold value are the same.

3. The method according to claim 1 , wherein the first threshold value and the second threshold value are different.

4. The method according to claim 1 , wherein the first threshold value is derived from control samples having an actual Gleason score of 6 or lower and the second threshold value is derived from control samples having an actual Gleason score of 7 or higher.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 21, 2022
From: KONICA MINOLTA, INC.
To: OTSUKA PHARMACEUTICAL CO., LTD.
Reel/Frame 059747/0589 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 20, 2018
From: KANEKO, TOMONORI; KAYA, TAKATOSHI
To: KONICA MINOLTA, INC.
Reel/Frame 045289/0099 →
Priority Claims (1)
JP JP2015-189611 · Sep 28, 2015 · national
Continuity (1)
Related Publication 20180348223A1 · Dec 6, 2018